These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 28608024

  • 1. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
    Dell'Oro R, Maloberti A, Nicoli F, Villa P, Gamba P, Bombelli M, Mancia G, Grassi G.
    High Blood Press Cardiovasc Prev; 2017 Dec; 24(4):393-400. PubMed ID: 28608024
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.
    Fonseca V, Zhu T, Karyekar C, Hirshberg B.
    Diabetes Obes Metab; 2012 Apr; 14(4):365-71. PubMed ID: 22192246
    [Abstract] [Full Text] [Related]

  • 8. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov 02; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract] [Full Text] [Related]

  • 9. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Nov 03; 15(1):150. PubMed ID: 27809848
    [Abstract] [Full Text] [Related]

  • 10. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC.
    Fertil Steril; 2017 Jan 03; 107(1):253-260.e1. PubMed ID: 28228317
    [Abstract] [Full Text] [Related]

  • 11. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.
    Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C.
    Diabetes Obes Metab; 2018 Jun 03; 20(6):1542-1546. PubMed ID: 29446523
    [Abstract] [Full Text] [Related]

  • 12. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
    Jadzinsky M, Pfützner A, Paz-Pacheco E, Xu Z, Allen E, Chen R, CV181-039 Investigators.
    Diabetes Obes Metab; 2009 Jun 03; 11(6):611-22. PubMed ID: 19515181
    [Abstract] [Full Text] [Related]

  • 13. Determinants of vascular function in patients with type 2 diabetes.
    Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S, Makriyiannis D, Tsatsoulis A, Michalis LK.
    Cardiovasc Diabetol; 2012 Oct 12; 11():127. PubMed ID: 23062182
    [Abstract] [Full Text] [Related]

  • 14. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
    Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto C, Inoue A, Tsuchida K, Manda N, Kurihara Y, Aoki S, Nakamura A, Atsumi T, SAIS Study Group.
    Cardiovasc Diabetol; 2017 Oct 10; 16(1):125. PubMed ID: 29017497
    [Abstract] [Full Text] [Related]

  • 15. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
    Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I.
    Int J Clin Pract; 2013 Apr 10; 67(4):307-16. PubMed ID: 23638466
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
    Karyekar C, Donovan M, Allen E, Fleming D, Ravichandran S, Chen R.
    Postgrad Med; 2011 Jul 10; 123(4):63-70. PubMed ID: 21680990
    [Abstract] [Full Text] [Related]

  • 17. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J, Sankoh S, List JF.
    Diabetes Obes Metab; 2008 May 10; 10(5):376-86. PubMed ID: 18355324
    [Abstract] [Full Text] [Related]

  • 18. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K, PROTECT Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):133. PubMed ID: 27619983
    [Abstract] [Full Text] [Related]

  • 19. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R.
    Curr Med Res Opin; 2012 Apr 13; 28(4):513-23. PubMed ID: 22313154
    [Abstract] [Full Text] [Related]

  • 20. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar 26; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.